Treatment News : Reclast Boosts Bone Density for at Least Five Years in HIV Study - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 1, 2012

Reclast Boosts Bone Density for at Least Five Years in HIV Study

by Tim Horn

Two annual doses of Reclast (zoledronate) improved bone health for up five years in a small study involving HIV-positive people with bone mineral deficiency, according to a study to be published by New Zealand researchers in the June issue of The Journal of Clinical Endocrinology & Metabolism (JCEM).

Bone mineral loss—known as osteopenia when it is mild to moderate and osteoporosis when it is more severe—is a disorder that most commonly strikes women after they’ve gone through menopause, people with thyroid problems and people who’ve taken corticosteroids for many years. There have been increasing reports in recent years, however, of younger HIV-positive women and men with bone mineral loss. Unfortunately, few studies have looked at osteopenia and osteoporosis treatments in people living with HIV.

To explore the potential of zoledronate, which has been approved as an annual injection for women with osteopenia and osteoporosis in the United States, Mark Bolland, MBChB, of the department of medicine at the University of Auckland in New Zealand and his colleagues initially conducted a two-year study involving 43 men living with HIV. The study volunteers took vitamin D and calcium supplements plus annual 15-minute intravenous infusions of either Reclast or placebo for two years.

The study’s original two-year results were published in April 2007 in JCEM. The more recent results focus on a four-year extension period in which the researchers assessed the long-term effects of Reclast administration during the original study.

Upon entering the trial, the men averaged 49 years of age, had been living with HIV for about eight years and were all on antiretroviral therapy. The average bone mineral density (BMD) T-score was -0.5—a half standard deviation below the average for a healthy 30-year-old adult of the same sex and ethnicity—which reflects relatively mild amounts of bone loss in this group of study volunteers.

In brief, at the end of the original two-year follow-up point, BMD of the spine increased 8.9 percent in the Reclast group (compared with 2.6 percent in the placebo group); BMD of the hip increased 3.8 percent compared with a 0.8 percent decrease; and total body BMD increased by 2.3 percent compared with a 0.5 percent decrease in the two groups, respectively.

Of the original 43 men, 31 received both annual injections and reported for follow-up for an additional four years—technically five years after they received their second dose.

At the end of the follow-up period, or six years after entering the study, participants’ measurements for spine, hip and total body BMD remained 3.5, 3.4 and 1.6 percent higher among those treated with Reclast compared with placebo.

Bolland and his colleagues also noted that blood levels of osteocalcin and beta-C-terminal telopeptide of type I collagen (CTX) remained significantly lower—38 and 49 percent, respectively—at the end of the follow-up period among those treated with Reclast compared with placebo. Both osteocalcin and CTX are biochemical markers for the bone breakdown and formation process. Studies have demonstrated that elevations in these markers are relatively well correlated with bone diseases characterized by increased bone turnover, especially osteopenia and osteoporosis.

While the study wasn’t designed to compare bone fracture rates between the two groups—the ultimate goal of treatment with medications like Reclast is to reduce the risk of serious fractures—Bolland and his colleagues noted that two fractures occurred during the follow-up period. Both fractures were among patients who received placebo infusions during the main two-year study.

Reclast was generally well-tolerated during the original two-year follow-up period, with no differences between those who received active drug or placebo during the extension period.

“The effects of two annual doses of zoledronate in men persist for at least five years after the second dose,” Bolland and his colleagues conclude. “Larger trials assessing the anti-fracture efficacy of less frequent dosing of zoledronate are justified.”

Search: reclast, zoledronate, osteopenia, osteoporosis, bone, bone mineral density, bmd, osteoclasts, beta-C-terminal telopeptide of type I collagen, ctx, Bolland

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.